14. 慢性炎症性脱髄性多発神経炎／多巣性運動ニューロパチー Disease details / Clinical trials / Drug dev / DR info

0.9% sodium chloride
   University of Toronto
      2015   Phase 4   NCT02372149   Canada
10% liquid formulation OF human immunoglobulin
   CSL Behring
      2010   Phase 3   NCT01184846   Belgium;Finland;France;Germany;Poland
ACT-HIB
   ARGENX BV
      2022   Phase 2   EUCTR2021-003302-50-IT   Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
ANTI-C5 antibody
   Greater Glasgow and Clyde NHS Board and The University Of Glasgow
      2009   -   EUCTR2008-005748-18-GB   United Kingdom
ANTI-thymocyte globulin
   Fred Hutchinson Cancer Center
      2008   Phase 2   NCT00716066   United States
ARGX-113
   ARGENX BV
      2020   Phase 2   EUCTR2019-003107-35-IT   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-IT   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
   argenx BVBA
      2021   Phase 2   EUCTR2019-003107-35-RO   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2019-003107-35-CZ   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2019-003107-35-AT   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2019-003076-39-RO   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2019-003076-39-AT   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003107-35-PL   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003107-35-NL   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003107-35-HU   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003107-35-GB   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003107-35-FR   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003107-35-ES   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003107-35-DK   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003107-35-DE   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003107-35-BG   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003107-35-BE   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-PL   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-NL   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-LV   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-HU   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-GB   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-ES   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-DK   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-DE   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-CZ   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-BG   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-BE   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
ARGX-117
   argenx
      2023   Phase 2   NCT05405361   Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2   NCT05225675   Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
ARGX-117 IV
   ARGENX BV
      2022   Phase 2   EUCTR2021-004998-32-IT   Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-003302-50-IT   Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
   argenx BV
      2023   Phase 2   EUCTR2021-004998-32-DE   Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2023   Phase 2   EUCTR2021-004998-32-AT   Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004998-32-NL   Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004998-32-FR   Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004998-32-ES   Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004998-32-BE   Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-003302-50-PL   Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-003302-50-NL   Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-003302-50-FR   Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-003302-50-ES   Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-003302-50-DE   Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-003302-50-BE   Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-003302-50-AT   Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Autologous hematopoietic stem cell transplantation
   Fred Hutchinson Cancer Center
      2008   Phase 2   NCT00716066   United States
Batoclimab
   Immunovant Sciences, GmbH
      2023   Phase 2   EUCTR2022-002718-17-SK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-SE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-RO   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-NO   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-FI   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-DK   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-DE   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-BG   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-BE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
Batoclimab 340 MG SC weekly
   Immunovant Sciences GmbH
      2022   Phase 2   NCT05581199   Argentina;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Italy;Korea, Republic of;Norway;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
Batoclimab 680 milligrams (MG) subcutaneous (SC) weekly
   Immunovant Sciences GmbH
      2022   Phase 2   NCT05581199   Argentina;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Italy;Korea, Republic of;Norway;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
BIVV020
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 2   EUCTR2020-004006-54-IT   Canada;China;France;Germany;Italy;Netherlands;Poland;Serbia;Spain;United Kingdom;United States
   Sanofi-Aventis Recherche & Développement
      2021   Phase 2   EUCTR2020-004006-54-PL   Canada;China;France;Germany;Italy;Netherlands;Poland;Serbia;Spain
      2021   Phase 2   EUCTR2020-004006-54-NL   Canada;China;France;Germany;Italy;Netherlands;Poland;Serbia;Spain
      2021   Phase 2   EUCTR2020-004006-54-FR   France;Germany;Italy;Netherlands;Poland
      2021   Phase 2   EUCTR2020-004006-54-DE   Canada;China;France;Germany;Italy;Netherlands;Poland;Serbia;Spain
Carmustine
   Fred Hutchinson Cancer Center
      2008   Phase 2   NCT00716066   United States
Clorfenamina maleato
   IRCCS ISTITUTO CLINICO HUMANITAS
      2018   Phase 3   EUCTR2017-005034-36-IT   Italy
Cyclophosphamide
   Stony Brook University
      2003   Phase 2   NCT01236456   United States
Cytarabine
   Fred Hutchinson Cancer Center
      2008   Phase 2   NCT00716066   United States
Dexamethasone
   AMC Medical research BV
      2006   -   EUCTR2004-002783-24-GB   United Kingdom
DNTH103
   Dianthus Therapeutics
      2025   Phase 3   NCT06858579   United States
      2024   Phase 2   NCT06537999   Denmark;Poland;United States
Eculizumab
   Greater Glasgow and Clyde NHS Board and The University Of Glasgow
      2009   -   EUCTR2008-005748-18-GB   United Kingdom
Efgartigimod
   argenx
      2023   -   NCT06299748   United States
Efgartigimod alfa
   ARGENX BV
      2020   Phase 2   EUCTR2019-003107-35-IT   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-IT   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
   argenx BVBA
      2021   Phase 2   EUCTR2019-003107-35-RO   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2019-003107-35-CZ   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2019-003107-35-AT   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2019-003076-39-RO   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2019-003076-39-AT   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003107-35-PL   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003107-35-NL   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003107-35-HU   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003107-35-GB   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003107-35-FR   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003107-35-ES   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003107-35-DK   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003107-35-DE   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003107-35-BG   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003107-35-BE   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-PL   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-NL   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-LV   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-HU   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-GB   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-ES   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-DK   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-DE   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-CZ   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-BG   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-BE   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
Efgartigimod PH20 SC
   ARGENX BV
      2020   Phase 2   EUCTR2019-003107-35-IT   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-IT   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
   argenx
      2024   Phase 4   NCT06637072   United States
      2020   Phase 2   NCT04280718   Austria;Belgium;Bulgaria;China;Czechia;Denmark;France;Georgia;Germany;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
   argenx BVBA
      2021   Phase 2   EUCTR2019-003107-35-RO   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2019-003107-35-CZ   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2019-003107-35-AT   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2019-003076-39-RO   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2019-003076-39-AT   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003107-35-PL   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003107-35-NL   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003107-35-HU   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003107-35-GB   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003107-35-FR   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003107-35-ES   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003107-35-DK   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003107-35-DE   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003107-35-BG   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003107-35-BE   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-PL   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-NL   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-LV   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-HU   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-GB   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-ES   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-DK   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-DE   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-CZ   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-BG   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003076-39-BE   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
Efgartigimod PH20 SC IN stage B
   argenx
      2020   Phase 2   NCT04281472   Austria;Belgium;Bulgaria;China;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
Empasiprubart
   argenx
      2025   Phase 3   NCT06920004   -
      2024   Phase 3   NCT06742190   United States
Etoposide
   Fred Hutchinson Cancer Center
      2008   Phase 2   NCT00716066   United States
Fampridine
   Department of Neurology, Odense University Hospital
      2020   Phase 2   EUCTR2020-002438-34-DK   Denmark
Fampyra
   Department of Neurology, Odense University Hospital
      2020   Phase 2   EUCTR2020-002438-34-DK   Denmark
Fibrinogen concentrate
   University Medical Centre Ljubljana
      2018   -   NCT03801135   Slovenia
Fingolimod
   Mitsubishi Tanabe Pharma Corporation, Novartis Pharma K.K.
      2012   Phase 3   JPRN-jRCT2080221916   -
Fingolimod hydrochloride
   NOVARTIS PHARMA AG
      2012   Phase 3   EUCTR2011-005280-24-IT   Australia;Belgium;Canada;Czech Republic;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
   Novartis Pharma Services AG
      2015   Phase 2;Phase 3   EUCTR2011-005280-24-CZ   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Serbia;Spain;United Kingdom;United States
      2013   Phase 2;Phase 3   EUCTR2011-005280-24-PL   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
      2013   Phase 2;Phase 3   EUCTR2011-005280-24-NL   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
      2012   Phase 2;Phase 3   EUCTR2011-005280-24-GR   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
      2012   Phase 2;Phase 3   EUCTR2011-005280-24-GB   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
      2012   Phase 2;Phase 3   EUCTR2011-005280-24-DE   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
      2012   Phase 2;Phase 3   EUCTR2011-005280-24-BE   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
Fresh frozen plasma
   University Medical Centre Ljubljana
      2018   -   NCT03801135   Slovenia
FTY720I
   NOVARTIS PHARMA AG
      2012   Phase 3   EUCTR2011-005280-24-IT   Australia;Belgium;Canada;Czech Republic;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
   Novartis Pharma Services AG
      2015   Phase 2;Phase 3   EUCTR2011-005280-24-CZ   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Serbia;Spain;United Kingdom;United States
      2013   Phase 2;Phase 3   EUCTR2011-005280-24-PL   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
      2013   Phase 2;Phase 3   EUCTR2011-005280-24-NL   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
      2012   Phase 2;Phase 3   EUCTR2011-005280-24-GR   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
      2012   Phase 2;Phase 3   EUCTR2011-005280-24-GB   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
      2012   Phase 2;Phase 3   EUCTR2011-005280-24-ES   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
      2012   Phase 2;Phase 3   EUCTR2011-005280-24-DE   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
      2012   Phase 2;Phase 3   EUCTR2011-005280-24-BE   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
Gammanorm
   Aarhus Unversity Hospital
      2017   Phase 4   EUCTR2017-002024-24-DK   Denmark
Gilenya
   Novartis Pharma Services AG
      2012   Phase 2;Phase 3   EUCTR2011-005280-24-GR   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
Gilenya 0,5 MG Cápsulas duras
   Novartis Pharma Services AG
      2012   Phase 2;Phase 3   EUCTR2011-005280-24-ES   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
Group C meningococcal conjugate vaccine
   ARGENX BV
      2022   Phase 2   EUCTR2021-003302-50-IT   Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
H.P. acthar® GEL
   Mamatha Pasnoor, MD
      2015   Phase 2   NCT02574962   United States
HB-admscs
   Hope Biosciences Stem Cell Research Foundation
      2022   -   NCT04825626   United States
HBM9161
   Immunovant Sciences, GmbH
      2023   Phase 2   EUCTR2022-002718-17-SK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-SE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-RO   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-NO   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-FI   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-DK   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-DE   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-BG   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-BE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
Hematopoietic stem cell transplantation
   Northwestern University
      2005   Phase 2   NCT00278629   United States
Hidrocloruro DE fingolimod
   Novartis Pharma Services AG
      2012   Phase 2;Phase 3   EUCTR2011-005280-24-ES   Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
Hizentra
   Aarhus University Hospital
      2019   Phase 4   EUCTR2018-003592-34-DK   Denmark
      2013   Phase 2   EUCTR2013-001428-20-DK   Denmark
   Aarhus Unversity Hospital
      2017   Phase 4   EUCTR2017-002024-24-DK   Denmark
   CSL BEHRING GMBH
      2012   Phase 3   EUCTR2011-003448-28-IT   Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;Germany;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
   CSL Behring
      2022   -   NCT04672733   France
   CSL Behring GmbH
      2015   Phase 3   EUCTR2013-004157-24-CZ   Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
      2015   Phase 3   EUCTR2011-003448-28-PL   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2015   -   EUCTR2011-003448-28-LT   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2011-003448-28-EE   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004157-24-NL   Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
      2014   Phase 3   EUCTR2013-004157-24-IT   Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States
      2014   Phase 3   EUCTR2013-004157-24-GB   Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004157-24-FI   Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
      2014   Phase 3   EUCTR2013-004157-24-ES   Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States
      2014   Phase 3   EUCTR2013-004157-24-DE   Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
      2012   Phase 3   EUCTR2011-003448-28-NL   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003448-28-GB   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003448-28-FI   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003448-28-ES   Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003448-28-DE   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003448-28-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003448-28-BE   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2012   -   EUCTR2011-003448-28-AT   Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Spain;Switzerland;United Kingdom;United States
HL161BKN
   Immunovant Sciences, GmbH
      2023   Phase 2   EUCTR2022-002718-17-SK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-SE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-RO   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-NO   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-FI   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-DK   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-DE   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-BG   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-BE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
Human immunoglobulin G
   Aarhus University Hospital
      2019   Phase 4   EUCTR2018-003592-34-DK   Denmark
   Aarhus Unversity Hospital
      2017   Phase 4   EUCTR2017-002024-24-DK   Denmark
Human normal immunoglobulin
   ARGENX BV
      2022   Phase 2   EUCTR2021-003302-50-IT   Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
   Aarhus University Hospital
      2013   Phase 2   EUCTR2013-001428-20-DK   Denmark
   Baxter Innovations GmbH
      2009   -   EUCTR2009-013841-27-DK   Denmark
   CSL BEHRING GMBH
      2012   Phase 3   EUCTR2011-003448-28-IT   Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;Germany;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
   CSL Behring GmbH
      2015   Phase 3   EUCTR2013-004157-24-CZ   Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
      2015   Phase 3   EUCTR2011-003448-28-PL   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2015   -   EUCTR2011-003448-28-LT   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2011-003448-28-EE   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004157-24-NL   Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
      2014   Phase 3   EUCTR2013-004157-24-IT   Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States
      2014   Phase 3   EUCTR2013-004157-24-GB   Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004157-24-FI   Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
      2014   Phase 3   EUCTR2013-004157-24-ES   Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States
      2014   Phase 3   EUCTR2013-004157-24-DE   Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
      2012   Phase 3   EUCTR2011-003448-28-NL   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003448-28-GB   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003448-28-FI   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003448-28-ES   Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003448-28-DE   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003448-28-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003448-28-BE   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2012   -   EUCTR2011-003448-28-AT   Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Spain;Switzerland;United Kingdom;United States
      2010   -   EUCTR2009-017672-24-FI   Finland
      2010   Phase 3   EUCTR2009-017672-24-BE   Belgium;Finland
   LFB BIOTECHNOLOGIES
      2016   Phase 3   EUCTR2013-005558-31-DE   France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom
      2015   Phase 3   EUCTR2013-005558-31-GB   France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom
      2015   Phase 3   EUCTR2013-005558-31-FR   France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom
      2015   Phase 3   EUCTR2013-005558-31-ES   France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom
   Rigshospitalet
      2015   Phase 2   EUCTR2015-003453-18-DK   Denmark
   Teijin Pharma Limited
      2014   Phase 3   JPRN-jRCT2080222422   Japan
      2014   Phase 3   JPRN-jRCT2080222421   Japan
Human normal immunoglobulin FOR intravenous administration
   LFB BIOTECHNOLOGIES
      2016   Phase 3   EUCTR2013-005557-73-DE   France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom
      2015   Phase 3   EUCTR2012-001995-12-IT   France;Italy;Spain;United Kingdom
      2014   Phase 3   EUCTR2013-005557-73-IT   France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom
      2014   Phase 3   EUCTR2013-005557-73-GB   France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom
      2014   Phase 3   EUCTR2013-005557-73-FR   France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom
      2014   Phase 3   EUCTR2013-005557-73-ES   France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom
      2013   Phase 3   EUCTR2012-001995-12-GB   France;Italy;Spain;United Kingdom
      2013   Phase 3   EUCTR2012-001995-12-FR   France;Spain;United Kingdom
      2013   Phase 3   EUCTR2012-001995-12-ES   France;Spain;United Kingdom
   Laboratoire français de Fractionnement et de Biotechnologies
      2013   Phase 3   NCT01951924   France;Italy;Spain;United Kingdom
Hyqvia
   Johannes Jakobsen
      2016   Phase 2   NCT02556437   Denmark
   Rigshospitalet
      2015   Phase 2   EUCTR2015-003453-18-DK   Denmark
   Takeda
      2025   Phase 3   NCT06747351   -
   UMC Utrecht
      2016   Phase 3   EUCTR2015-000828-28-NL   Netherlands
I10
   LFB BIOTECHNOLOGIES
      2016   Phase 3   EUCTR2013-005558-31-DE   France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom
      2016   Phase 3   EUCTR2013-005557-73-DE   France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom
      2015   Phase 3   EUCTR2013-005558-31-GB   France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom
I10E
   LFB BIOTECHNOLOGIES
      2015   Phase 3   EUCTR2013-005558-31-IT   France;Germany;Italy;Mexico;Morocco;Spain;Turkey;United Kingdom
      2015   Phase 3   EUCTR2013-005558-31-FR   France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom
      2015   Phase 3   EUCTR2013-005558-31-ES   France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom
      2015   Phase 3   EUCTR2012-001995-12-IT   France;Italy;Spain;United Kingdom
      2014   Phase 3   EUCTR2013-005557-73-IT   France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom
      2014   Phase 3   EUCTR2013-005557-73-GB   France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom
      2014   Phase 3   EUCTR2013-005557-73-FR   France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom
      2014   Phase 3   EUCTR2013-005557-73-ES   France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom
      2013   Phase 3   EUCTR2012-001995-12-GB   France;Italy;Spain;United Kingdom
      2013   Phase 3   EUCTR2012-001995-12-FR   France;Spain;United Kingdom
      2013   Phase 3   EUCTR2012-001995-12-ES   France;Spain;United Kingdom
   Laboratoire français de Fractionnement et de Biotechnologies
      2013   Phase 3   NCT01951924   France;Italy;Spain;United Kingdom
Igpro10
   CSL BEHRING GMBH
      2012   Phase 3   EUCTR2011-003448-28-IT   Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;Germany;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
   CSL Behring
      2019   Phase 4   NCT03684018   Canada;United States
      2012   Phase 3   NCT01545076   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Estonia;Finland;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
   CSL Behring GmbH
      2015   Phase 3   EUCTR2011-003448-28-PL   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2015   -   EUCTR2011-003448-28-LT   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2011-003448-28-EE   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003448-28-NL   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003448-28-GB   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003448-28-FI   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003448-28-ES   Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003448-28-DE   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003448-28-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003448-28-BE   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2012   -   EUCTR2011-003448-28-AT   Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Spain;Switzerland;United Kingdom;United States
Igpro20
   CSL Behring
      2014   Phase 3   NCT02027701   Australia;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
      2012   Phase 3   NCT01545076   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Estonia;Finland;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
   CSL Behring GmbH
      2015   Phase 3   EUCTR2013-004157-24-CZ   Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
      2015   Phase 3   EUCTR2011-003448-28-PL   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2015   -   EUCTR2011-003448-28-LT   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2011-003448-28-EE   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004157-24-NL   Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
      2014   Phase 3   EUCTR2013-004157-24-IT   Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States
      2014   Phase 3   EUCTR2013-004157-24-GB   Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004157-24-FI   Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
      2014   Phase 3   EUCTR2013-004157-24-ES   Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States
      2014   Phase 3   EUCTR2013-004157-24-DE   Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
      2012   Phase 3   EUCTR2011-003448-28-NL   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003448-28-GB   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003448-28-FI   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003448-28-ES   Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003448-28-DE   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003448-28-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003448-28-BE   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2012   -   EUCTR2011-003448-28-AT   Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Spain;Switzerland;United Kingdom;United States
Igvena*FL 200ML 10G+SET
   KEDRION
      2007   -   EUCTR2005-001136-76-IT   Italy
Immune globulin
   Baxalta now part of Shire
      2008   Phase 3   NCT00666263   Canada;Denmark;Netherlands;Poland;United States
   National Center for Research Resources (NCRR)
      1992   Phase 3   NCT00004772   -
   Nishizawa Atsushi
      2021   Phase 3   JPRN-jRCT2051210110   -
   University of South Florida
      2014   -   NCT02465359   United States
Immune globulin (human) 10% solution FOR intravenous administration
   Kedrion S.p.A.
      2025   Phase 3   NCT06752356   -
Immune globulin 10% intravenous solution
   Vera Bril
      2017   Phase 3   NCT03166527   Canada
Immune globulin IV (human), 10% caprylate/chromatography purified
   Grifols Therapeutics Inc.
      2004   Phase 3   NCT00220740   Argentina;Canada;Czech Republic;Former Serbia and Montenegro;Germany;Israel;Italy;Mexico;Poland;Serbia;United States
Immunoadsorption
   University of Ulm
      2023   Phase 2   NCT04881682   Germany
Immunoglobulin
   University of Aarhus
      2020   Phase 4   NCT04589299   Denmark
Immunoglobulin G
   CSL Behring AG
      2008   Phase 2   EUCTR2007-000710-37-GB   Germany;Italy;United Kingdom
      2007   -   EUCTR2007-000710-37-DE   Germany;Italy;United Kingdom
   CSL Behring GmbH
      2010   -   EUCTR2009-017672-24-FI   Finland
      2010   Phase 3   EUCTR2009-017672-24-BE   Belgium;Finland
   Octapharma Pharmazeutika Produktionsges.m.b.H.
      2017   Phase 3   EUCTR2015-005443-14-SE   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
      2017   Phase 3   EUCTR2015-005443-14-PL   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
      2017   Phase 3   EUCTR2015-005443-14-HU   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
      2017   Phase 3   EUCTR2015-005443-14-DK   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
      2017   Phase 3   EUCTR2015-005443-14-DE   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
      2017   Phase 3   EUCTR2015-005443-14-CZ   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
      2017   Phase 3   EUCTR2015-005443-14-BG   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
Immunoglobulin perfusion
   Centre Hospitalier Universitaire de Saint Etienne
      2004   Phase 3   NCT01349270   France
Immunoglobulina umana normale PER somministrazione endovenosa
   LFB BIOTECHNOLOGIES
      2015   Phase 3   EUCTR2013-005558-31-IT   France;Germany;Italy;Mexico;Morocco;Spain;Turkey;United Kingdom
Immunoglobuline G
   Octapharma AG
      2011   Phase 2;Phase 3   EUCTR2009-017805-13-CZ   Bulgaria;Czech Republic
      2011   -   EUCTR2009-017805-13-BG   Bulgaria;Czech Republic;India;Mexico;Poland;Romania;Serbia;Ukraine
      2010   Phase 2;Phase 3   EUCTR2009-017805-13-RO   Bulgaria;Czech Republic;Romania
Immunoglobulins
   CSL Behring AG
      2007   -   EUCTR2007-000710-37-IT   Germany;Italy;United Kingdom
   KEDRION
      2007   -   EUCTR2005-001136-76-IT   Italy
   Rigshospitalet, Denmark
      2014   -   NCT02111590   Denmark
   University of Ulm
      2023   Phase 2   NCT04881682   Germany
IMVT-1401
   Immunovant Sciences, GmbH
      2023   Phase 2   EUCTR2022-002718-17-SK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-SE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-RO   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-NO   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-FI   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-DK   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-DE   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-BG   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-BE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
Intratect
   ARGENX BV
      2022   Phase 2   EUCTR2021-003302-50-IT   Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Intravenous immune globulin G
   Rutgers, The State University of New Jersey
      2022   Phase 1   NCT05584631   United States
Intravenous immunoglobulin
   National Institute of Neurological Disorders and Stroke (NINDS)
      1990   Phase 2   NCT00001287   United States
   University of Aarhus
      2005   Phase 2   NCT00268788   Denmark
   University of Minnesota
      2015   -   NCT02414490   United States
   University of Toronto
      2015   Phase 4   NCT02372149   Canada
   argenx
      2024   Phase 3   NCT06742190   United States
Iqymune
   LFB BIOTECHNOLOGIES
      2016   Phase 3   EUCTR2013-005558-31-DE   France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom
      2016   Phase 3   EUCTR2013-005557-73-DE   France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom
      2015   Phase 3   EUCTR2013-005558-31-GB   France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom
      2014   Phase 3   EUCTR2013-005557-73-GB   France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom
Ivig
   ARGENX BV
      2022   Phase 2   EUCTR2021-003302-50-IT   Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
   National Institute of Neurological Disorders and Stroke (NINDS)
      1990   Phase 2   NCT00001287   United States
   Sanofi
      2024   Phase 3   NCT06290141   Argentina;Belgium;Brazil;Canada;China;Czechia;Denmark;Germany;Hungary;Israel;Japan;Mexico;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
   Tanaka Tomoyuki
      2024   Phase 3   JPRN-jRCT2031240206   Japan;United States
   University of Toronto
      2015   Phase 4   NCT02372149   Canada
   argenx
      2025   Phase 3   NCT06920004   -
      2024   Phase 3   NCT06742190   United States
Kiovig
   Erasmus MC
      2014   Phase 4   EUCTR2013-004988-32-NL   Netherlands
   LFB BIOTECHNOLOGIES
      2015   Phase 3   EUCTR2012-001995-12-IT   France;Italy;Spain;United Kingdom
      2013   Phase 3   EUCTR2012-001995-12-GB   France;Italy;Spain;United Kingdom
      2013   Phase 3   EUCTR2012-001995-12-FR   France;Spain;United Kingdom
      2013   Phase 3   EUCTR2012-001995-12-ES   France;Spain;United Kingdom
   Laboratoire français de Fractionnement et de Biotechnologies
      2013   Phase 3   NCT01951924   France;Italy;Spain;United Kingdom
Kiovig 100 MG/ML solution FOR infusion
   Baxter Innovations GmbH
      2009   -   EUCTR2009-013841-27-DK   Denmark
Laboratory biomarker analysis
   Fred Hutchinson Cancer Center
      2008   Phase 2   NCT00716066   United States
Lipoic acid
   Oregon Health and Science University
      2009   Phase 2   NCT00962429   United States
M281/JNJ-80202135
   Janssen-Cilag International NV
      2022   Phase 2;Phase 3   EUCTR2021-003234-37-SK   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-003234-37-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Türkiye;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-003234-37-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Türkiye;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-003234-37-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-003234-37-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-003234-37-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
Mabthera - 1 fiala 500 MG 50 ML
   IRCCS ISTITUTO CLINICO HUMANITAS
      2018   Phase 2   EUCTR2018-001347-31-IT   Italy
      2018   Phase 3   EUCTR2017-005034-36-IT   Italy
MD1003
   MedDay Pharmaceuticals SA
      2016   Phase 2   NCT02967679   France
Melphalan
   Fred Hutchinson Cancer Center
      2008   Phase 2   NCT00716066   United States
Menjugate
   ARGENX BV
      2022   Phase 2   EUCTR2021-003302-50-IT   Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Methylprednisolon
   Academisch Medisch Centrum
      2018   Phase 3   EUCTR2017-002511-34-NL   Netherlands;United Kingdom
Methylprednisolone
   Academic Medical Centre, Amsterdam, NL
      2019   Phase 3   EUCTR2017-002511-34-GB   Netherlands;United Kingdom
   Academisch Medisch Centrum
      2018   Phase 3   EUCTR2017-002511-34-NL   Netherlands;United Kingdom
Metilprednisolone sodio succinato
   IRCCS ISTITUTO CLINICO HUMANITAS
      2018   Phase 3   EUCTR2017-005034-36-IT   Italy
N. meningitidis group C polysaccharide
   ARGENX BV
      2022   Phase 2   EUCTR2021-003302-50-IT   Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Newgam
   Octapharma
      2017   Phase 3   NCT02638207   Australia;Bulgaria;Canada;Czechia;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
   Octapharma AG
      2011   Phase 2;Phase 3   EUCTR2009-017805-13-CZ   Bulgaria;Czech Republic
      2011   -   EUCTR2009-017805-13-BG   Bulgaria;Czech Republic;India;Mexico;Poland;Romania;Serbia;Ukraine
      2010   Phase 2;Phase 3   EUCTR2009-017805-13-RO   Bulgaria;Czech Republic;Romania
   Octapharma Pharmazeutika Produktionsges.m.b.H.
      2017   Phase 3   EUCTR2015-005443-14-SE   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
      2017   Phase 3   EUCTR2015-005443-14-PL   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
      2017   Phase 3   EUCTR2015-005443-14-HU   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
      2017   Phase 3   EUCTR2015-005443-14-DK   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
      2017   Phase 3   EUCTR2015-005443-14-DE   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
      2017   Phase 3   EUCTR2015-005443-14-CZ   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
      2017   Phase 3   EUCTR2015-005443-14-BG   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
Nipocalimab
   Janssen Research & Development, LLC
      2022   Phase 2/Phase 3   NCT05327114   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Taiwan;United Kingdom;United States
   Janssen-Cilag International NV
      2022   Phase 2;Phase 3   EUCTR2021-003234-37-SK   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-003234-37-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Türkiye;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-003234-37-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Türkiye;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-003234-37-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-003234-37-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-003234-37-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
   Nakano Masayoshi
      2022   Phase 2-3   JPRN-jRCT2041220037   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea,RepublicOf;Mexico;Poland;Portugal;Slovakia;Spain;Taiwan,ProvinceOf China;UnitedKingdomOf GreatBritainAndNorthernIreland;UnitedStates OfAmerica
NPB-01
   Nihon Pharmaceutical Co., Ltd
      2013   Phase 3   NCT01827072   Japan
      2013   Phase 3   NCT01824251   Japan
Panzyga
   Octapharma
      2023   Phase 3   NCT04929236   United States
   Octapharma Pharmazeutika Produktionsges.m.b.H.
      2017   Phase 3   EUCTR2015-005443-14-SE   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
      2017   Phase 3   EUCTR2015-005443-14-PL   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
      2017   Phase 3   EUCTR2015-005443-14-HU   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
      2017   Phase 3   EUCTR2015-005443-14-DK   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
      2017   Phase 3   EUCTR2015-005443-14-DE   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
      2017   Phase 3   EUCTR2015-005443-14-CZ   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
      2017   Phase 3   EUCTR2015-005443-14-BG   Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
Paracetamolo
   IRCCS ISTITUTO CLINICO HUMANITAS
      2018   Phase 3   EUCTR2017-005034-36-IT   Italy
Peripheral blood stem cell transplantation
   Fred Hutchinson Cancer Center
      2008   Phase 2   NCT00716066   United States
Prednisolone
   AMC Medical research BV
      2006   -   EUCTR2004-002783-24-GB   United Kingdom
Prednisone
   Centre Hospitalier Universitaire de Saint Etienne
      2004   Phase 3   NCT01349270   France
   Fred Hutchinson Cancer Center
      2008   Phase 2   NCT00716066   United States
Prevenar 13 sospensione PER iniezione
   ARGENX BV
      2022   Phase 2   EUCTR2021-003302-50-IT   Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Privigen
   Aarhus University Hospital
      2019   Phase 4   EUCTR2018-003592-34-DK   Denmark
      2013   Phase 2   EUCTR2013-001428-20-DK   Denmark
   CSL Behring GmbH
      2010   -   EUCTR2009-017672-24-FI   Finland
      2010   Phase 3   EUCTR2009-017672-24-BE   Belgium;Finland
Recombinant human hyaluronidase
   Nishizawa Atsushi
      2021   Phase 3   JPRN-jRCT2051210110   -
Rhuph20
   Nishizawa Atsushi
      2021   Phase 3   JPRN-jRCT2051210110   -
   UMC Utrecht
      2016   -   NCT02885259   Netherlands
Riliprubart
   Sanofi
      2025   Phase 3   NCT06859099   Canada;China
      2024   Phase 3   NCT06290141   Argentina;Belgium;Brazil;Canada;China;Czechia;Denmark;Germany;Hungary;Israel;Japan;Mexico;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2024   Phase 3   NCT06290128   Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United States
   Tanaka Tomoyuki
      2024   Phase 3   JPRN-jRCT2031240206   Japan;United States
      2024   Phase 3   JPRN-jRCT2031240109   Japan;United States
Ripertamab
   Zhongming Qiu
      2025   Phase 3   NCT06858722   -
Rituximab
   Amsterdam University Medical Center (UMC), Location Academic Medical Center (AMC)
      2024   Phase 3   NCT06714838   Netherlands
   IRCCS ISTITUTO CLINICO HUMANITAS
      2018   Phase 2   EUCTR2018-001347-31-IT   Italy
      2018   Phase 3   EUCTR2017-005034-36-IT   Italy
   Iijima Masahiro
      2019   Phase 2   JPRN-jRCT2041180037   -
   Katsuno Masahisa
      2021   Phase 2   JPRN-jRCTs041210046   -
   Nagoya University
      2019   Phase 2   NCT03864185   Japan
   Nagoya University Hospital
      2019   Phase 2   JPRN-UMIN000035753   Japan
   University of Kansas Medical Center
      2025   Phase 2   NCT04480450   -
Rozanolixizumab
   UCB Biopharma S.P.R.L.
      2019   Phase 2   NCT03861481   Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
   UCB Biopharma SPRL
      2020   Phase 2   EUCTR2018-004392-12-NL   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2018-004392-12-DE   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004392-12-GB   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004392-12-FR   Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004392-12-ES   Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004392-12-DK   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2016-002411-17-NL   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2016-002411-17-GB   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2016-002411-17-FR   Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2016-002411-17-ES   Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2016-002411-17-DK   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2016-002411-17-DE   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
   UCB Biopharma SRL
      2021   -   NCT05014724   -
      2019   Phase 2   NCT04051944   Belgium;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004392-12-BE   Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2016-002411-17-BE   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
RVG 51680
   Department of Neurology, Academic Medical Center
      2014   -   EUCTR2013-005363-52-NL   Netherlands
RVG 56083
   Academisch Medisch Centrum
      2018   Phase 3   EUCTR2017-002511-34-NL   Netherlands;United Kingdom
RVT-1401
   Immunovant Sciences, GmbH
      2023   Phase 2   EUCTR2022-002718-17-SK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-SE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-RO   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-NO   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-FI   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-DK   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-DE   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-BG   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 2   EUCTR2022-002718-17-BE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
SAR445088
   Bioverativ, a Sanofi company
      2021   Phase 2   NCT04658472   Canada;China;France;Germany;Italy;Netherlands;Poland;Serbia;Spain;United States
   Sanofi-Aventis Recherche & Développement
      2021   Phase 2   EUCTR2020-004006-54-PL   Canada;China;France;Germany;Italy;Netherlands;Poland;Serbia;Spain
      2021   Phase 2   EUCTR2020-004006-54-NL   Canada;China;France;Germany;Italy;Netherlands;Poland;Serbia;Spain
      2021   Phase 2   EUCTR2020-004006-54-DE   Canada;China;France;Germany;Italy;Netherlands;Poland;Serbia;Spain
   Tanaka Tomoyuki
      2024   Phase 3   JPRN-jRCT2031240206   Japan;United States
      2024   Phase 3   JPRN-jRCT2031240109   Japan;United States
SC investigational needle sets
   Takeda
      2025   Phase 3   NCT06747351   -
Sodium chloride
   Academic Medical Centre, Amsterdam, NL
      2019   Phase 3   EUCTR2017-002511-34-GB   Netherlands;United Kingdom
   Academisch Medisch Centrum
      2018   Phase 3   EUCTR2017-002511-34-NL   Netherlands;United Kingdom
   Department of Neurology, Academic Medical Center
      2014   -   EUCTR2013-005363-52-NL   Netherlands
Soliris
   Greater Glasgow and Clyde NHS Board and The University Of Glasgow
      2009   -   EUCTR2008-005748-18-GB   United Kingdom
Solu medrol - 125 MG/2 ML polvere E solvente PER soluzione iniettabile 1 flacone A doppia camera DA 125 MG/2 ML
   IRCCS ISTITUTO CLINICO HUMANITAS
      2018   Phase 3   EUCTR2017-005034-36-IT   Italy
Subcutaneous immune globulin G
   Rutgers, The State University of New Jersey
      2022   Phase 1   NCT05584631   United States
Subcutaneous immunoglobulin
   University of Aarhus
      2005   Phase 2   NCT00268788   Denmark
Subcuvia
   Aarhus Unversity Hospital
      2017   Phase 4   EUCTR2017-002024-24-DK   Denmark
   Johannes Jakobsen
      2016   Phase 2   NCT02556437   Denmark
   Rigshospitalet
      2015   Phase 2   EUCTR2015-003453-18-DK   Denmark
Syngeneic bone marrow transplantation
   Fred Hutchinson Cancer Center
      2008   Phase 2   NCT00716066   United States
TAK-411
   Takeda
      2025   Phase 2   NCT06798012   United States
TAK-771
   Nishizawa Atsushi
      2021   Phase 3   JPRN-jRCT2051210110   -
   Takeda
      2021   Phase 3   NCT05084053   Japan
TAK-881
   Takeda
      2025   Phase 3   NCT06747351   -
Tetanus toxoid
   ARGENX BV
      2022   Phase 2   EUCTR2021-003302-50-IT   Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Trimeton - 10 MG/1 ML soluzione iniettabile 5 fiale 1 ML
   IRCCS ISTITUTO CLINICO HUMANITAS
      2018   Phase 3   EUCTR2017-005034-36-IT   Italy
UCB7665
   UCB Biopharma SPRL
      2020   Phase 2   EUCTR2018-004392-12-NL   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2018-004392-12-DE   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004392-12-GB   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004392-12-FR   Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004392-12-ES   Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004392-12-DK   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2016-002411-17-NL   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2016-002411-17-GB   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2016-002411-17-FR   Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2016-002411-17-ES   Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2016-002411-17-DK   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2016-002411-17-DE   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
   UCB Biopharma SRL
      2019   Phase 2   EUCTR2018-004392-12-BE   Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2016-002411-17-BE   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
Vaccino pneumococcico saccaridico
   ARGENX BV
      2022   Phase 2   EUCTR2021-003302-50-IT   Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Vivaglobin
   CSL Behring
      2007   Phase 2   NCT00701662   Germany;Italy;Switzerland;United Kingdom
   CSL Behring AG
      2008   Phase 2   EUCTR2007-000710-37-GB   Germany;Italy;United Kingdom
      2007   -   EUCTR2007-000710-37-IT   Germany;Italy;United Kingdom
      2007   -   EUCTR2007-000710-37-DE   Germany;Italy;United Kingdom